Alpha-7 Nicotinic Agonist for Public Speaking Anxiety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for public speaking anxiety (PSA) and social anxiety disorder (SAD), including SAD-performance only subtype (SAD-PO), have limitations such as slow onset of action, high rates of partial response, and low rates of long-term remission, along with adverse effects from existing anxiolytics, necessitating a more effective and safer treatment option.
Innovation Solution
Administration of the potent and selective alpha 7 nicotinic acetylcholine receptor (α7 nAChR) agonist, (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, or its pharmaceutically acceptable salts, to treat and prevent symptoms of PSA and SAD, including as-needed use for anxiety-provoking situations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anxiolytic treatments (SSRIs, BZDs, MAOIs) are used for public speaking anxiety, then anxiety symptoms are partially reduced, but adverse effects occur and treatment response is slow with high rates of partial response only
Solution Approach 1:
The patent changes the pharmacological parameter by selecting a specific receptor target (alpha-7 nicotinic acetylcholine receptor) and optimizing the molecular structure of agonists to achieve selective binding. This parameter change in receptor specificity and molecular configuration enables effective anxiety treatment with reduced adverse effects compared to traditional anxiolytics that target broader neurotransmitter systems
Solution Approach 2:
The patent introduces an intermediary mechanism by using alpha-7 nAChR agonists as a mediator between the nervous system and anxiety symptoms. These compounds selectively activate alpha-7 receptors in brain regions involved in anxiety regulation, providing a targeted intermediary pathway that avoids the broad-sided effects and adverse reactions associated with traditional anxiolytics
2Reliability
If current anxiolytic treatments are used for public speaking anxiety, then some symptom relief is achieved, but onset of action is slow and long-term remission rates are low
Solution Approach 1:
The patent implements preliminary action by developing alpha-7 nAChR agonists that can be administered acutely before anxiety-provoking situations. This allows the medication to be present and active at the precise moment needed, providing rapid symptom relief without requiring weeks of continuous treatment buildup, thus addressing the slow onset problem of traditional SSRIs
3Reliability
If traditional anxiolytics are used for public speaking anxiety, then partial symptom relief is achieved, but complete resolution of symptoms is rarely obtained
Solution Approach 1:
The patent substitutes the mechanical/pharmacological system by replacing traditional neurotransmitter targets (serotonin, GABA, norepinephrine systems) with the alpha-7 nicotinic acetylcholine receptor system. This substitution creates a more effective therapeutic mechanism that achieves complete symptom resolution rather than partial relief, as the alpha-7 receptor system appears to more directly regulate the neural circuits involved in anxiety and fear responses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively reduces the severity of symptoms, prevents symptom progression, and provides complete resolution of anxiety symptoms in individuals with PSA and SAD, offering a safer and more effective alternative to existing treatments.
Implementation Method 1
Administration of the potent and selective alpha 7 nicotinic acetylcholine receptor (α7 nAChR) agonist, (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane
Data Source
AI summary
Disclosed herein is a method of treatment or prevention of public speaking anxiety (PSA), which may in some cases present as a symptom of social anxiety disorder (SAD), including the performance only (SAD-PO) subtype of SAD. The method of treatment includes administering an a7 nAChR agonist such as (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane to the individual at a therapeutically effective dose.